Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Hiroaki Baba, Hajime Kanamori, Kengo Oshima, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Yukio Sato, Koichi Tokuda, Tetsuji Aoyagi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

Original languageEnglish
Pages (from-to)1100-1103
Number of pages4
JournalJournal of Infection and Chemotherapy
Volume26
Issue number10
DOIs
Publication statusPublished - 2020 Oct
Externally publishedYes

Keywords

  • Ciclesonide
  • Coronavirus disease 2019
  • Iguratimod
  • Viral shedding

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide'. Together they form a unique fingerprint.

Cite this